About RDD Pharma
RDD Pharma is a company based in Tel Aviv (Israel) founded in 2008 was acquired by Innovate Biopharma in October 2019. RDD Pharma has raised $16.65 million across 3 funding rounds from investors including PharmaScience, Orbimed and Innovate Biopharma. RDD Pharma offers products and services including Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani. RDD Pharma operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
- Headquarter Tel Aviv, Israel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rdd Pharma, Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.65 M (USD)
in 3 rounds
-
Latest Funding Round
$9.5 M (USD), Series B
Nov 16, 2017
-
Investors
PharmaScience
& 3 more
-
Employee Count
Not available
-
Acquired by
Innovate Biopharma
(Oct 07, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RDD Pharma
RDD Pharma offers a comprehensive portfolio of products and services, including Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani.
Proprietary system for targeted delivery of treatments to anorectal regions.
Repurposed drug compound for managing fecal incontinence symptoms.
Repurposed medication targeting pruritus ani and related conditions.
People of RDD Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of RDD Pharma
RDD Pharma has successfully raised a total of $16.65M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $9.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RDD Pharma
RDD Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include PharmaScience, Orbimed and Innovate Biopharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Early-stage real estate startups are funded by Capital Point.
|
Locked | Locked | Locked | |
|
Generic, branded, and over-the-counter pharmaceuticals are manufactured for global markets.
|
Locked | Locked | Locked |
Investor details for RDD Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RDD Pharma
Investment portfolio details for RDD Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RDD Pharma
Detailed financials for RDD Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rdd Pharma Comparisons
Peer comparison for RDD Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RDD Pharma
RDD Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
Detailed competitors of RDD Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rdd Pharma
Complete news archive for RDD Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RDD Pharma
RDD Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
RDD Pharma is headquartered in Tel Aviv, Israel.
RDD Pharma is a funded company, having raised a total of $16.65M across 3 funding rounds to date.
RDD Pharma is a clinical stage company focussed on developing drugs and delivery systems for anorectal and gastrointestinal disorders. It is targeting the space between generics and NCEs to develop its pipeline. It is currently initiating a phase 3 study for the treatment of chronic anal fissure with its lead product RDD 1219 along with a sustained release drug delivery device Capository. It also completed phase 2a study of RDD 0315 for fecal incontinence Pruritus Ani. Besides, it has a preclinical program for Radiation Colitis.
RDD Pharma's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
RDD Pharma offers Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani.
RDD Pharma has 4 investors. Key investors include PharmaScience, Orbimed, Innovate Biopharma, and Capital Point.